Our proprietary PCR-based in vitro molecular diagnostics assays, SensiScreen® and PlentiPlex™, for detection of somatic mutations in solid and liquid biopsies offers sensitive and ease-of-hand use. Based on PentaBase’s novel and selective INA® technologies SensiScreen® and PlentiPlex™ provide complementary diagnostics and monitoring of key disease gene mutations; including BRAF, KRAS, EGFR, NRAS, KIT, MYD88 and PIK3CA.
SensiScreen
Cancer Mutations
Our proprietary real-time PCR-based SensiScreen® and PlentiPlex™ MYD88 L265P assays for somatic mutation detection in cancer patients combine ultra-high sensitivity with multiplexing capabilities, speed, ease-of-use and little hands-on-time. Complementary diagnostics and monitoring of key cancer genes in solid and liquid biopsies.
PlentiPlex MSI
Microsatellite Instability
PlentiPlex™ MSI assays for in vitro diagnosis of impaired mismatch repair (MMR) affecting prognosis and selection of treatment in cancer patients. The PlentiPlex™ MSI assays offer length analysis of five multiplexed microsatellite loci recommended by the Bethesda and Hamelin guidelines.
PlentiPlex Mastocytosis
Mastocytosis
Mastocytosis is a disorder characterized by growth and accumulation of neoplastic mast cells within various organs and most commonly the skin. PlentiPlex™ Mastocytosis assay is designed to identify the presence of the KIT D816V mutation in mast cells to assist the diagnosis of mastocytosis.
We offer solutions for microsatellite instability analysis. We cover both Bethesda and Hamelins panel.